| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
|
Purity: ≥98%
Temsavir (formerly known as BMS626529; BMS-626529) is a novel, potent attachment inhibitor that targets HIV-1 gp120 and prevents its binding to CD4+ T cells. Temsavir is also the phosphonooxymethyl prodrug of BMS-626529 that targets HIV-1 gp120 and prevents its binding to CD4(+) T cells. BMS-626529 had half-maximal effective concentration (EC(50)) values of<10 nm, with half-maximal effective concentration values in the low pM range against the most susceptible viruses.
| Targets |
HIV-1
|
|---|---|
| ln Vitro |
Half-maximal effective concentration (EC50) values for temsavir against the majority of viral isolates are less than 10 nM. Temsavir has an average EC50 of 0.7±0.4 nM against the LAI virus. When it comes to the most susceptible virus, temsavir has an EC50 of 0.01 nM, and when it comes to the least susceptible virus, it is >2,000 nM. Temsavir's cytotoxicity profile is investigated in a variety of cell types from various human tissues. Following three or six days in culture, CC50 values of >200 μM were found in MT-2 (t lymphocytes), HEK293 (kidney), HEp-2 (larynx), HepG2 (liver), HeLa (cervix), HCT116 (colorectal), MCF-7 (breast), SK-N-MC (neuroepithelium), HOS (bone), H292 (lung), and MDBK (bovine kidney) cells.After six days in culture, PBMCs and the T-cell line PM1 have CC50 values of 192 μM and 105 μM, respectively. Temsavir demonstrates minimal cytotoxicity in cell culture, according to these findings[1]. Against a panel of clinical isolates, temsavir demonstrates a wide range of antiviral activity, with a 50% inhibitory concentration (IC50) that spans from subnanomolar levels to >0.1 µM[2].
|
| Enzyme Assay |
The binding of [3H]Temsavir or [3H]BMS-488043 to gp120 is measured using Micro BioSpin 6 columns. Binding solutions (30 μL) with serial dilutions of [3H]BMS-488043 or [3H]Temsavir, 125 mM NaCl, 50 nM gp120JRFL, and 25 mM Tris-HCl (pH 7.5) are allowed to equilibrate before being adsorbed to a MicroBioSpin 6 column. After five minutes of centrifuging the column at about 14,000 rpm, the eluent is collected, and a scintillation counter is used to measure radioactivity.Dissociative kinetics are measured by first achieving equilibrium binding with 60 nM gp120 at room temperature for 1 h, then adding a large molar excess (14-fold) of soluble CD4 protein to drive dissociation. This process is repeated with 150 nM [3H]Temsavir or 90 nM [3H]BMS-488043. The radioactivity in the eluent is quantified after aliquots are taken at the designated intervals, adsorbed to a spin column, and centrifuged. Percentage of compound bound was determined by comparing the tritium signal between parallel samples with and without the soluble CD4 challenge[1].
|
| Cell Assay |
Cell viability is measured using an XTT assay, and cytotoxicity tests are conducted for up to six days in the presence of serially diluted Temsavir. Initially, 0.1×106 cells/mL is the plating density of laboratory-adapted peripheral blood mononuclear cells (PBMCs) in order to calculate CC50 values (drug concentration needed to kill 50% of cells). Cell densities in the absence of compounds usually reach 1×106 to 1.2×106/mL after 6 days[1].
|
| References |
|
| Molecular Formula |
C24H23N7O4
|
|---|---|
| Molecular Weight |
473.48392
|
| Exact Mass |
473.18
|
| Elemental Analysis |
C, 60.88; H, 4.90; N, 20.71; O, 13.52
|
| CAS # |
701213-36-7
|
| Related CAS # |
Fostemsavir;864953-29-7;Fostemsavir Tris;864953-39-9
|
| Appearance |
White to off-white solid powder.
|
| SMILES |
O=C(N1CCN(C(C2=CC=CC=C2)=O)CC1)C(C3=CNC4=C3C(OC)=CN=C4N5N=C(C)N=C5)=O
|
| InChi Key |
QRPZBKAMSFHVRW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C24H23N7O4/c1-15-27-14-31(28-15)22-20-19(18(35-2)13-26-22)17(12-25-20)21(32)24(34)30-10-8-29(9-11-30)23(33)16-6-4-3-5-7-16/h3-7,12-14,25H,8-11H2,1-2H3
|
| Chemical Name |
1-(4-benzoylpiperazin-1-yl)-2-(4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione
|
| Synonyms |
BMS-626529; BMS 626529; BMS626529
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 16.67 mg/mL (~35.21 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.67 mg/mL (3.53 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.67 mg/mL (3.53 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.67 mg/mL (3.53 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1120 mL | 10.5601 mL | 21.1202 mL | |
| 5 mM | 0.4224 mL | 2.1120 mL | 4.2240 mL | |
| 10 mM | 0.2112 mL | 1.0560 mL | 2.1120 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
|
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
